Structure Therapeutics (GPCR) Net Income (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Net Income of -$76.0 million for Q1 2026, down 62.21% year-over-year from -$201.0 million in Q1 2025, and down 142.73% quarter-over-quarter from $177.8 million in Q4 2025.
Structure Therapeutics (GPCR) Net Income (2022 - 2026) Analysis & Trends
Structure Therapeutics' Net Income history runs 5 years deep, the most recent figure standing at -$76.0 million for Q1 2026.
- In Q1 2026, Net Income fell 62.21% year-over-year to -$76.0 million; the TTM figure through Mar 2026 stood at -$25.6 million (up 15.47% YoY), while the FY2025 annual figure was $3.6 million, up 137.9% from the prior year.
- Net Income for Q1 2026 stood at -$76.0 million, down from $177.8 million in the prior quarter.
- The five-year high for Net Income was $177.8 million in Q4 2025, with the low at -$76.0 million in Q1 2026.
- The 5-year median for Net Income is -$23.3 million (2023), against an average of -$5.8 million.
- Peak annual rise in Net Income reached 132.06% in 2025, while the deepest fall reached 136.85% in 2025.
- Structure Therapeutics' Net Income stood at $32.3 million in 2022, then soared by 72.31% to $55.7 million in 2023, then soared by 37.55% to $76.6 million in 2024, then soared by 132.06% to $177.8 million in 2025, then slumped by 142.73% to -$76.0 million in 2026.
- Business Quant data shows GPCR's Net Income at -$76.0 million in Q1 2026, $177.8 million in Q4 2025, and -$65.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -106.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -106.16 Mn |
| Mar 31, 2026 | -75.97 Mn |
| Dec 31, 2025 | 177.78 Mn |
| Sep 30, 2025 | -65.71 Mn |
| Jun 30, 2025 | -61.66 Mn |
| Mar 31, 2025 | -46.83 Mn |
| Dec 31, 2024 | 76.61 Mn |
| Sep 30, 2024 | -33.98 Mn |
| Jun 30, 2024 | -26.03 Mn |
| Mar 31, 2024 | -26.04 Mn |
| Dec 31, 2023 | 55.70 Mn |
| Sep 30, 2023 | -23.86 Mn |
| Jun 30, 2023 | -23.28 Mn |
| Mar 31, 2023 | -17.98 Mn |
| Dec 31, 2022 | 32.32 Mn |
| Sep 30, 2022 | -12.42 Mn |
| Jun 30, 2022 | -13.95 Mn |
| Mar 31, 2022 | -13.08 Mn |